Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level

Journal of the Medical Association of Thailand

Volumn 98, Issue 1, 2015, Pages 21-25

  Kangkarn, Supanatcha ^a   Boonyapisit, Warangkna ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Atorvastatin; LDL; Rosuvastatin; Simvastatin; Statin

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; ESSENTIAL DRUG; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; BLOOD; MIDDLE AGED; THAILAND;

DRUGS, ESSENTIAL; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN; SULFONAMIDES; THAILAND;

EID: 84924330468     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
2. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72.
3. Tunceli K, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, et al. Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients. J Clin Lipidol 2010; 4: 491-500.
4. Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clin Ther 2008; 30: 1345-57.
5. Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006; 151: 975-9.
6. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe inpatients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-80.
7. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91: 667-72.
8. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192: 432-7.
9. Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147: E18.
10. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PW, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 515-23.
11. Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 2007; 13 (Suppl 10): S270-5.